HealthcareTirzepatide more effective in blood sugar control and body...

Tirzepatide more effective in blood sugar control and body weight loss than semaglutide, shows meta-analysis


Tirzepatide more effective in blood sugar control and body weight loss than semaglutide, shows meta-analysis
Credit: CC0 Public Domain

A new meta-analysis combining 22 studies, to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2–6 October), shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms of amount of body weight lost by patients. The study is by Dr. Thomas Karagiannis, Aristotle University of Thessaloniki, Thessaloniki, Greece, and colleagues.

Semaglutide is approved for treatment of type 2 diabetes and also obesity/weight loss management. Tirzepatide has been approved for treating type 2 diabetes and its manufacturers have submitted applications for its approval for obesity/weight loss management.

There are few randomized controlled trials (RCTs) directly comparing subcutaneous tirzepatide with subcutaneous semaglutide. In this new research, the authors combined the data from 22 available trials to perform a to compare tirzepatide with semaglutide in terms of their efficacy and safety in people with type 2 diabetes.

The authors searched Medline and the Cochrane Library for RCTs that assessed a maintenance dose of subcutaneous tirzepatide 5, 10, or 15 mg once-weekly or subcutaneous semaglutide 0.5, 1.0, or 2.0 mg once-weekly for at least 12 weeks.

Comparators were any of the eligible doses of tirzepatide and semaglutide, placebo, and also other glucose-lowering drugs provided they were directly compared to tirzepatide and semaglutide in at least one trial. The meta-analysis then calculated any differences in effects on HbA1c (glycated hemoglobin, a measure of blood sugar control), body weight, and also the risk of adverse events.

The 22 RCTs included data from 18,472 patients, all with a diagnosis of type 2 diabetes. The authors found that tirzepatide 15 mg was the most efficacious in reducing HbA1c versus placebo (mean difference -2.00%), followed by tirzepatide 10 mg (-1.86%) and semaglutide 2.0 mg (-1.62%).

Each of the three tirzepatide doses reduced HbA1c more than the respective low-, medium-, and high-dose of semaglutide. Versus placebo, tirzepatide was more efficacious in reducing body weight (-10.96 Kg, -8.75 Kg, and -6.16 Kg for tirzepatide 15, 10, and 5 mg respectively) than semaglutide (-5.24 Kg, -4.44 Kg, and -2.72 Kg for semaglutide 2.0, 1.0, and 0.5 mg respectively).

Regarding between-drug comparisons, both tirzepatide 10 and 15 mg were more efficacious in lowering body weight versus semaglutide 0.5, 1.0, and 2.0 mg, while tirzepatide 5 mg was more efficacious versus semaglutide 0.5 and 1.0 mg.

Although not in the journal abstract, the authors have been able to provide results for change in body weight from the analyses comparing tirzepatide and semaglutide (rather than versus placebo). These numerical values will be presented in the oral presentation in the congress.

The actual differences in change in (mean difference) for the following comparisons are:

  • Tirzepatide 15 mg versus semaglutide 2.0 mg = -5.72 Kg (i.e., a mean of 5.72 Kg more weight lost in those taking tirzepatide 15 mg versus those taking semaglutide 2.0 mg)
  • Tirzepatide 10 mg versus semaglutide 2.0 mg = -3.52 Kg
  • Tirzepatide 5 mg versus semaglutide 1.0 mg = -1.72 Kg

The authors explain, “In summary the three tirzepaide doses were more effective than the three respective semaglutide doses, with the difference between the two drugs being larger with the .”

As compared to placebo, all doses of tirzepatide and semaglutide increased risk for gastrointestinal adverse events, with tirzepatide 15 mg yielding the highest increased risk (3.6 times) for nausea, vomiting (4.4 times) and diarrhea (double the risk).

Between-drug comparisons yielded non-statistically significant results, except for tirzepatide 15 mg versus semaglutide 1.0 mg (39% increased vomiting risk) and 0.5 mg (85% increased vomiting risk), and tirzepatide 15 mg versus semaglutide 0.5 mg (45% increased risk of nausea). There was no difference between tirzepatide, semaglutide and placebo regarding risk for serious adverse events.

The authors conclude, “In people with type 2 diabetes, tirzepatide 5, 10, and 15 mg were more efficacious in reducing HbA1c compared to semaglutide 0.5, 1.0, and 2.0 mg, respectively. Tirzepatide also was also more effective for weight loss than semaglutide, with a larger -loss effect at higher doses. High-dose tirzepatide (15 mg) was associated with increased risk for vomiting versus low- and medium-dose semaglutide.”

Citation:
Tirzepatide more effective in blood sugar control and body weight loss than semaglutide, shows meta-analysis (2023, September 22)
retrieved 22 September 2023
from https://medicalxpress.com/news/2023-09-tirzepatide-effective-blood-sugar-body.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Original Source Link

Latest News

China’s car sales snap five-month decline on subsidy boost

A heavy traffic jam with many cars on the road in Chaoyang district in Beijing, China.Sw Photography |...

Bitcoin ETFs end three-day skid with $254M inflow

The $254 million inflow day was the third-largest ever on days when BlackRock’s IBIT failed to contribute. Original Source...

From beans to chips, vertical integration differs from older models

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly...

Leak: AMD’s Ryzen 9000X3D chips aren’t looking like a leap forward

According to slides from an MSI presentation published by HardwareLuxx today (via VideoCardz), the new chips may have...

Kamala Harris Blasts Trump For Trashing Detroit

The Harris campaign blasted Trump in a new ad after the ex-president trashed the city of Detroit. Video: https://www.youtube.com/watch?v=BPgQp2VuZwQ Transcript of...

Science news quiz, October 12, 2024: Do you know your meteor showers from your massive millipedes?

The weekend is here, and what better time to look back at the week in science news by...

Must Read

- Advertisement -

You might also likeRELATED
Recommended to you